Cobimetinib is an N-acylazetidine derived from the selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. It is a mitogen-activated protein kinase inhibitor used in combination with vemurafenib to treat unresectable or metastatic melanoma, administered as its fumarate salt. Cobimetinib functions as an EC 2.7.11.24 inhibitor and antineoplastic agent. It belongs to piperidines, N-acylazetidines, tertiary alcohols, aromatic amines, secondary amino compounds, difluorobenzenes, and organoiodine compounds. It is the conjugate base of cobimetinib(1+).
